Macrophages are critical effectors of antibody therapies for cancer

mAbs

Volumn 7, Issue 2, 2015, Pages 303-310

  Weiskopf, Kipp ^a,b   Weissman, Irving L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

ADCP; Antibodies; Cancer; CD47; Fc receptor; Immune checkpoint; Immunotherapy; Macrophages; Phagocytosis; SIRP

Indexed keywords

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; CD47 ANTIGEN; FC RECEPTOR; CANCER ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY ENGINEERING; CANCER IMMUNOTHERAPY; HUMAN; MACROPHAGE; PHAGOCYTOSIS; REVIEW; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, NEOPLASM; HUMANS; MACROPHAGES; NEOPLASMS; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 84924602786     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1011450     Document Type: Review

References (81)

1. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/ JCO.2011.38.0899
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/ nature10673
3. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333-47; PMID:24274181; http:// dx.doi.org/10.1146/annurev-med-060512-150254
4. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65:185-202; PMID:24188664; http://dx.doi.org/10.1146/annurev-med-092012-112807
5. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-61; PMID:20133564; http://dx.doi.org/10.1126/ science.1178331
6. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111:927-30; PMID:12507420; http://dx.doi.org/10.1016/ S0092-8674(02)01201-1
7. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-37; PMID:21997792; http://dx.doi.org/ 10.1038/nri3073
8. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56:4625-9; PMID:8840975
9. Bingle L, Brown NJ, Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-65; PMID:11857487; http://dx.doi.org/ 10.1002/path.1027
10. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005; 23:953-64; PMID:15598976; http://dx.doi.org/10.1200/JCO.2005.12.172
11. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169-74; PMID:15933054; http://dx.doi.org/10.1182/blood-2005-04-1565
12. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008; 14:1423-30; PMID:18316565; http:// dx.doi.org/10.1158/1078-0432.CCR-07-1712
13. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362:875-85; PMID:20220182; http://dx.doi.org/10.1056/ NEJMoa0905680
14. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-96; PMID:20856220; http://dx.doi.org/10.1038/ni.1937
15. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86:1065-73; PMID:19741157; http://dx.doi. org/10.1189/jlb.0609385
16. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25:846-59; PMID:24898549; http://dx.doi.org/10.1016/j. ccr.2014.05.016
17. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/ nri2206
18. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; http://dx.doi. org/10.1182/blood-2012-01-380121
19. Johnson WD, Jr., Mei B, Cohn ZA. The separation, long-term cultivation, and maturation of the human monocyte. J Exp Med 1977; 146:1613-26; PMID:925613; http://dx.doi.org/10.1084/ jem.146.6.1613
20. Becker S, Warren MK, Haskill S. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J Immunol 1987; 139:3703-9; PMID:2824612
21. Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 1990; 172:231-7; PMID:2193096; http://dx.doi.org/ 10.1084/jem.172.1.231
22. Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, Vidarsson G, ten Hagen TL, Kubes P, van Egmond M. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124:812-23; PMID:24430180; http://dx. doi.org/10.1172/JCI66776
23. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A 1982; 79:4761-5; PMID:6289317; http://dx.doi.org/10.1073/ pnas.79.15.4761
24. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221:865-7; PMID:6879183; http://dx.doi. org/10.1126/science.6879183
25. Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci U S A 1984; 81:3506-10; PMID:6587365; http://dx.doi. org/10.1073/pnas.81.11.3506
26. Chaperot L, Chokri M, Jacob MC, Drillat P, Garban F, Egelhofer H, Molens JP, Sotto JJ, Bensa JC, Plumas J. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000; 14:1667-77; PMID:10995015; http://dx.doi.org/10.1038/sj. leu.2401888
27. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54; PMID:12393572; http://dx.doi.org/10.1182/blood-2002-02-0469
28. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006; 29:388-97; PMID:16799334; http://dx.doi.org/ 10.1097/01.cji.0000203081.43235.d7
29. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699-713; PMID:20813259; http://dx.doi.org/10.1016/j.cell.2010.07.044
30. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; http://dx.doi.org/10.4049/ jimmunol.1000303
31. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182:4415-22; PMID:19299742; http://dx.doi.org/10.4049/jimmunol.0713732
32. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013; 341:88-91; PMID:23722425; http:// dx.doi.org/10.1126/science.1238856
33. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-61; PMID:3500259; http://dx.doi.org/10.1084/jem.166.5.1351
34. Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 1999; 53:199-207; PMID:10369066; http://dx. doi.org/10.1023/A:1006145507567
35. Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Muhlenberg T, Montgomery KD, Contre-ras-Trujillo H, Czechowicz A, Fletcher JA, et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A 2013; 110:3501-6; PMID:23382202; http:// dx.doi.org/10.1073/pnas.1222893110
36. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/10.1084/ jem.20040119
37. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174:817-26; PMID:15634903; http://dx.doi.org/10.4049/ jimmunol.174.2.817
38. Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123:5098-103; PMID:24177426; http://dx.doi.org/10.1172/ JCI70972
39. van der Bij GJ, Bogels M, Otten MA, Oosterling SJ, Kuppen PJ, Meijer S, Beelen RH, van Egmond M. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocytemediated monoclonal antibody therapy. J Hepatol 2010; 53:677-85; PMID:20619916; http://dx.doi.org/ 10.1016/j.jhep.2010.04.023
40. Grugan Kd, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Strohl WR, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189:5457-66; PMID:23105143; http://dx.doi.org/10.4049/ jimmunol.1201889
41. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10.1200/ JCO.2003.05.013
42. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
43. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25:3712-8; PMID:17704420; http://dx.doi.org/10.1200/JCO.2006.08.8021
44. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011; 22:1302-7; PMID:21109570; http://dx.doi.org/ 10.1093/annonc/mdq585
45. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclo-phosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13:5784-9; PMID:17908969; http:// dx.doi.org/10.1158/1078-0432.CCR-07-0778
46. Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Quittet P, Klein B, Rossi JF. Granulocytemacrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008; 26:2725-31; PMID:18427151; http://dx.doi.org/10.1200/ JCO.2007.13.7729
47. Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. International journal of cancer Journal international du cancer 2014; 135:2199-205; PMID:24644014; http://dx.doi.org/10.1002/ijc.28851
48. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/10.1126/science.1198443
49. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000; 288:2051-4; PMID:10856220; http://dx.doi.org/10.1126/ science.288.5473.2051
50. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138:271-85; PMID:19632178; http://dx.doi. org/10.1016/j.cell.2009.05.046
51. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr., van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99; PMID:19632179; http://dx. doi.org/10.1016/j.cell.2009.05.045
52. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109:6662-7; PMID:22451913; http://dx.doi. org/10.1073/pnas.1121623109
53. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 2012; 109:6656-61; PMID:22451919; http://dx.doi. org/10.1073/pnas.1121629109
54. Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997; 386:181-6; PMID:9062191; http://dx.doi.org/ 10.1038/386181a0
55. Adams S, van der Laan LJ, Vernon-Wilson E, Renardel de Lavalette C, Dopp EA, Dijkstra CD, Simmons DL, van den Berg TK. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 1998; 161:1853-9; PMID:9712053
56. Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 1999; 274:559-62; PMID:9872987; http://dx.doi.org/10.1074/ jbc.274.2.559
57. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 2014; 32:25-50; PMID:24215318; http://dx.doi.org/10.1146/annurev-immunol-032713-120142
58. Lienard H, Bruhns P, Malbec O, Fridman WH, Daeron M. Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. J Biol Chem 1999; 274:32493-9; PMID:10542295; http:// dx.doi.org/10.1074/jbc.274.45.32493
59. Tsai RK, Discher DE. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008; 180:989-1003; PMID:18332220; http://dx.doi.org/ 10.1083/jcb.200708043
60. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193:855-62; PMID:11283158; http://dx.doi.org/10.1084/jem.193.7.855
61. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011; 108:18342-7; PMID:22042861; http://dx.doi.org/10.1073/ pnas.1106550108
62. Harrison RE, Grinstein S. Phagocytosis and the microtubule cytoskeleton. Biochemistry and cell biology D Biochimie et biologie cellulaire 2002; 80:509-15; PMID:12440692; http://dx.doi.org/10.1139/o02-142
63. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123:1957-60; PMID:24652965; http://dx.doi.org/ 10.1182/blood-2014-01-547869
64. Roit FD, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015; 100:77-86; PMID:25344523; http://dx.doi.org/ 10.3324/haematol.2014.107011
65. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatmentnaive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet Oncology 2014; 15:1019-26; PMID:25042202; http://dx.doi.org/10.1016/S1470-2045(14)70311-0
66. Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 1979; 63:61-6; PMID:286835
67. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014; 156:590-602; PMID:24485462; http://dx.doi. org/10.1016/j.cell.2013.12.041
68. Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014; 192:2252-60; PMID:24489098; http://dx.doi.org/10.4049/ jimmunol.1301249
69. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/ pnas.0508123103
70. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68:8049-57; PMID:18829563; http://dx.doi.org/10.1158/0008-5472.CAN-08-2268
71. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Jr., Roda JM, Cheney C, Mo X, Lehman A, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115:1204-13; PMID:19965644; http://dx.doi.org/10.1182/blood-2009-06-229039
72. Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 2014; 124:3553-60; PMID:25301708; http://dx.doi.org/ 10.1182/blood-2014-08-593269
73. Kelton W, Mehta N, Charab W, Lee J, Lee CH, Kojima T, Kang TH, Georgiou G. IgGA: A "Cross-Isotype" Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions. Chem Biol 2014; 21:1603-9; PMID:25500223; http://dx.doi.org/10.1016/j.chembiol.2014.10.017
74. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001; 75:12161-8; PMID:11711607; http://dx.doi.org/ 10.1128/JVI.75.24.12161-12168.2001
75. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-4; PMID:18560159; http://dx.doi.org/10.1107/ S0907444908007877
76. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995; 55:4586-93; PMID:7553634
77. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Kohl U, Durkop H, Engert A, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Molecular therapy : the journal of the American Society of Gene Therapy 2013; 21:895-903; PMID:23459515; http://dx.doi.org/10.1038/ mt.2013.14
78. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13:2281-92; PMID:7545221
79. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII 2008; 57:155-63; PMID:17602224; http://dx.doi.org/ 10.1007/s00262-007-0357-5
80. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000; 165:5112-21; PMID:11046042; http://dx. doi.org/10.4049/jimmunol.165.9.5112
81. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, et al. Anti-CD47 antibodymediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 2013; 110:11103-8; PMID:23690610; http://dx.doi.org/10.1073/ pnas.1305569110